Financial Performance - The group's revenue increased by approximately RMB 171.5 million or 20.9% to about RMB 992.0 million for the year ended December 31, 2022[10]. - The group's gross profit rose by approximately RMB 143.2 million or 24.8% to about RMB 720.9 million for the same period[10]. - The group's EBITDA increased by approximately RMB 143.1 million or 50.8% to about RMB 424.9 million for the year ended December 31, 2022[10]. - Profit attributable to equity holders increased by approximately RMB 93.6 million or 49.9% to about RMB 281.2 million compared to the previous year[10]. - For the year ended December 31, 2022, the company's revenue was approximately RMB 992.0 million, an increase of about RMB 171.5 million or 20.9% compared to RMB 820.5 million for the year ended December 31, 2021[61]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 904.6 million, up by RMB 165.4 million or 22.4% from RMB 739.2 million in the previous year[61]. - The sales volume of Jin Sangzi throat lozenges (OTC) reached 126,686 thousand boxes, with a gross margin of 74.0%[62]. - Net profit for the year ended December 31, 2022, was approximately RMB 281.2 million, an increase of approximately RMB 93.6 million or 49.9% from approximately RMB 187.6 million for the year ended December 31, 2021[76]. - Gross profit for the year ended December 31, 2022, was approximately RMB 720.9 million, an increase of approximately RMB 143.2 million or 24.8% from approximately RMB 577.7 million for the year ended December 31, 2021, with a gross margin of 72.7%[67]. Product Development and Market Strategy - The company launched a new product, Golden Throat Probiotic Tablets, developed in collaboration with Beijing Agricultural University, targeting the lack of proprietary probiotics in China[14]. - The company aims to strengthen its brand core with sub-brands like "Throat Treasure," "Intestinal Treasure," and "Heart Treasure" to capture high-end market segments[15]. - The company is confident in achieving breakthroughs in the pharmaceutical and fast-moving consumer goods sectors in 2023[18]. - The company plans to continue investing in research and development for new products and technologies to maintain competitive advantage[31]. - The company is focusing on developing new products such as gene drugs, traditional Chinese medicine formulas, and health food products to drive growth in the health industry[59]. - The company aims to strengthen its brand recognition and market presence through enhanced digital marketing and advertising strategies[57]. - The company has successfully developed 32 new products since 1994, obtaining production licenses for 8 pharmaceutical products and 22 food products[42]. Market Presence and Recognition - The company received recognition as a leading enterprise in Guangxi and was awarded the most popular brand at the Guangxi Brand High-Quality Development Forum[12]. - In 2022, the company was ranked 48th among China's OTC production enterprises and received the title of "Most Popular Brand" at the Guangxi Brand High-Quality Development Forum[31]. - The flagship product, Golden Throat Lozenges (OTC), accounted for approximately 91.2% of the total revenue for the year ended December 31, 2022[35]. - The company has established a comprehensive national sales and distribution network covering all provinces, autonomous regions, and municipalities in China as of December 31, 2022[45]. - The company has signed agency agreements with all 10 ASEAN countries, successfully exporting products to nine of them[48]. - As of December 31, 2022, the Jin Sang Zi throat treasure series products have been exported to 22 countries and regions, with new additions including France, Spain, the Netherlands, Italy, and Ireland in 2022[44]. Operational Efficiency and Future Plans - The company completed the relocation to a new base and purchased an additional 50 acres of land for the Phase II project, which includes various research institutes[15]. - The company plans to enhance its production capacity through the construction of a new production base, which has a total area of approximately 60,000 square meters[58]. - The new production base will include a research and development center, production plant, warehouse, and administrative office building, aimed at improving manufacturing quality and competitiveness[58]. - The group plans to establish a health industry park and enhance its core competitiveness over the next decade[90]. - The group has initiated the exploration and surveying phase for the construction of a food production plant and R&D center[92]. Financial Management and Governance - The company is committed to maintaining high standards of corporate governance and compliance with regulatory requirements[31]. - The company has a strong focus on financial management, with key personnel having nearly three decades of experience in the field[110]. - The company has adopted a stable dividend policy, prioritizing a relatively certain cash dividend distribution amount as the primary profit distribution goal[126]. - The company reported a final dividend of HKD 0.36 per share for the year ended December 31, 2022, subject to shareholder approval[120]. - The financial statements for the year ended December 31, 2022, include a detailed review of the group's profit and financial position[119]. Challenges and Risks - The board's report includes discussions on future business development and potential risks and uncertainties facing the group[122]. - The management anticipates stable growth in sales as the pandemic situation improves and consumer demand increases[31]. - The company has not reported any significant events after the reporting period[89]. Shareholder Information - As of December 31, 2022, the total shares held by the founder of the trust amounted to 516,013,700 shares, representing approximately 69.79% of the total issued shares[163]. - The family trust holds 453,025,800 shares, representing approximately 61.28% of the total issued shares[169]. - The senior management trust holds 58,937,400 shares, accounting for 7.97% of the total issued shares[169]. - The company’s board and senior management have not reported any changes in their interests in shares or related securities as per the relevant regulations[161]. - The total number of shares that can be issued under the stock option plan is capped at 10% of the total issued shares as of the approval date, which amounts to 73,930,200 shares[155]. Related Party Transactions - The company engaged in related party transactions with Guangxi Changbao Biotechnology Co., Ltd., purchasing raw materials and finished products amounting to RMB 31,110 thousand, with actual transaction value of RMB 2,446 thousand for the year ended December 31, 2022[183]. - The company has a framework agreement with Changbao for the procurement of sugar substitute raw materials, which was renewed for the period from January 1, 2021, to December 31, 2023[186].
金嗓子(06896) - 2022 - 年度财报